Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine, Adjuvanted With MPLA Liposomes, in Healthy, HIV-Uninfected Adults

Phase 1 Active not recruiting 12 enrolled Fundacion Clinic per a la Recerca Biomédica Polymun Scientific GmbH · collab

NaSingle-groupOpen-labelPrevention

Summary

Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine, Adjuvanted with MPLA Liposomes, in Healthy, HIV-Uninfected Adults

Timeline

Start: 2023-07-24
Primary completion: 2025-06
Completion: 2025-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	763SIP8	Protein / enzyme biologic	100 ug	Intramuscular
Background	MPLA	Unknown	500 ug	Intramuscular

Indications

No indication recorded.